ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for ...
On Tuesday, Alzamend Neuro Inc (NASDAQ:ALZN) said it finished analyzing the final full data set from a nonclinical study comparing brain and plasma lithium exposures between AL001 and lithium ...
Alzamend is developing AL001, a lithium product designed for enhanced safety and efficacy compared to currently available FDA-approved and marketed lithium therapies At a low dose, AL001 evidenced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results